You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ)擬放棄樂普生物增資優先認購權
格隆匯 07-29 19:44

格隆匯 7 月 29日丨樂普醫療(300003.SZ)公佈,2020年7月29日,公司召開第五屆董事會第七次會議,審議通過《關於放棄對參股公司樂普生物科技有限公司增資優先認購權暨關聯交易》的議案。公司綜合考慮自身情況、經營規劃,決議放棄對樂普生物此輪增資的優先認購權。此輪增資後,公司持有樂普生物的股權比例不低於15.08%。

樂普生物目前註冊資本126,573.87萬元人民幣,擬進行新一輪的股權融資,融資金額不超過13億元人民幣,計入註冊資本不超過22,853.61萬元人民幣,增資後的註冊資本不超過149,427.48萬元人民幣。

樂普生物圍繞腫瘤免疫治療和靶向藥物,已建立起單雙抗體、溶瘤病毒、抗體偶聯藥等多個生物藥開發技術平台,多個產品在臨牀管線中穩步推進。此次通過引入新股東增資,樂普生物將獲得較為充裕的資金更好的開展業務,擴展經營規模,增強經營能力、盈利能力,同時有效降低上市公司的投資風險。

公司放棄此次增資的優先認購權,此次增資完成後公司持有樂普生物的股權比例不低於15.08%,樂普生物仍為公司的參股公司,公司的合併報表範圍沒有發生變化,對公司財務狀況、經營成果、未來主營業務和持續經營能力不構成重大影響,不存在損害公司及股東特別是中小股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account